Snapshot from May 30, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / ADMA Biologics Stock Drops on Fraud Claims
Regulatory securities fraud

ADMA Biologics Stock Drops on Fraud Claims

Analysis based on 8 articles · First reported May 01, 2026 · Last updated May 13, 2026

Sentiment
-70
Attention
4
Articles
8
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The market is impacted by the significant stock drop of ADMA Biologics, reflecting investor concern over alleged securities fraud and channel stuffing. This event highlights the risks associated with financial reporting irregularities and could lead to a class-action lawsuit, affecting shareholder confidence in ADMA Biologics.

Biotechnology Legal Services
Event Summary

ADMA Biologics is under investigation by Bleichmar Fonti & Auld LLP for potential securities fraud. This follows a report by Culper Research on March 24, 2026, alleging that ADMA Biologics engaged in a 'channel stuffing' scheme in 2025. The report claims that ADMA Biologics induced a distributor to stock excess ASCENIV through rebates and extended payment terms, artificially inflating its reported 20% revenue growth for 2025. Culper Research suggests that without this alleged scheme, ADMA Biologics would have seen a 3% revenue decline. Following this news, ADMA Biologics' stock price plummeted by 29%, or $3.96 per share, over two trading days from March 23 to March 25, 2026. Bleichmar Fonti & Auld LLP is encouraging investors who suffered losses to seek legal options.

Key Actions
100 ADMA Biologics stock declined
95 ADMA Biologics induced distributor stock
90 Culper Research published report ADMA Biologics
85 Bleichmar Fonti & Auld LLP announced investigation ADMA Biologics
Entities Involved
stock
ADMA Biologics
ADMA Biologics is being investigated for securities fraud due to alleged channel stuffing, which caused its stock to drop significantly. The company's reported 20% revenue growth in 2025 is under scrutiny.
Importance 100 Sentiment -80
priv
Bleichmar Fonti & Auld LLP
Bleichmar Fonti & Auld LLP (BFA Law) is a leading securities law firm that initiated the investigation into ADMA Biologics for potential violations of federal securities laws.
Importance 80 Sentiment 50
priv
Culper Research
Culper Research is an investigative research firm that published a report alleging ADMA Biologics engaged in channel stuffing, which led to the stock drop and subsequent investigation.
Importance 70 Sentiment 40
per
Adam McCall
Adam McCall is a contact person at Bleichmar Fonti & Auld LLP for investors interested in the ADMA Biologics investigation.
Importance 10 Sentiment 0
stock
Tesla, Inc.
Tesla, Inc. is mentioned as a company from which Bleichmar Fonti & Auld LLP previously recovered a significant amount in a separate case, demonstrating the law firm's track record.
Importance 0 Sentiment 0
stock
Sun Pharma
Sun Pharma is mentioned as a company from which Bleichmar Fonti & Auld LLP previously recovered a significant amount in a separate case, demonstrating the law firm's track record.
Importance 0 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.